BioLineRx Ltd. (Nasdaq: BLRX) signed an exclusive, global agreement with BGN Technologies, the Technology Transfer Company of Ben-Gurion Universioty and Hadasit for the in-licensing of the liver failure treatment BL-1220. The stock price climbed 27 cents to close at $1.28.
BioLineRx signs exclusive agreement
September 23, 2016 at 19:47 PM EDT